Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020117620 - METHOD, SYSTEM AND KIT TO DETECT METASTATIC HEPATIC CANCER STEMMING FROM COLORECTAL TUMORS AND TO DETERMINE A PROPOSED TREATMENT REGIME

Publication Number WO/2020/117620
Publication Date 11.06.2020
International Application No. PCT/US2019/063862
International Filing Date 29.11.2019
IPC
C12Q 1/6886 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
G01N 33/53 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
G16B 25/10 2019.01
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
25ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
10Gene or protein expression profiling; Expression-ratio estimation or normalisation
CPC
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/106
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/118
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
118Prognosis of disease development
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
G16B 20/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
20ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 30/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
30ICT specially adapted for sequence analysis involving nucleotides or amino acids
Applicants
  • PERSONA BIOMED, INC. [US]/[US]
Inventors
  • VIDAL-VANACLOCHA, Fernando
Agents
  • HARBIN, Lawrence
Priority Data
16/209,52104.12.2018US
16/210,48605.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD, SYSTEM AND KIT TO DETECT METASTATIC HEPATIC CANCER STEMMING FROM COLORECTAL TUMORS AND TO DETERMINE A PROPOSED TREATMENT REGIME
(FR) PROCÉDÉ, SYSTÈME ET KIT POUR DÉTECTER UN CANCER HÉPATIQUE MÉTASTATIQUE PROVENANT DE TUMEURS COLORECTALES ET POUR DÉTERMINER UN TRAITEMENT PROPOSÉ
Abstract
(EN)
Method, system and kit for early detection of metastatic hepatic cancer in colorectal tumor patients at the subclinical stage comprising analyzing genetic expression levels of tumor-free hepatic tissue of said patients against reference values of corresponding genes derived from tumor-free persons. A processor implementing the method interprets significance of overexpression and/or underexpression of such genes relative to said reference values to produce an indication confirming or dispelling hepatic metastasis. Specific genes include group 1 (PRDX4, CRP, ID1, MT1E, TNFSF14, MRC1, ICAM1, IL18, IL10, TFN) and group 2 (NGF, EPHA1, ERBB2IP, SDC1, COL18A1, KNG1, ADH1B, CYP2E1). Analysis also may be performed on protein signatures of these genes to produce a similar indication. The method may be used with a kit comprising a low density genetic expression array or protein array for measuring genetic expressions or protein signatures.
(FR)
L'invention concerne un procédé, un système et un kit pour la détection précoce d'un cancer hépatique métastatique chez des patients atteints de tumeur colorectale au stade subclinique, comprenant l'analyse de niveaux d'expression génétique de tissu hépatique exempt de tumeur desdits patients par rapport à des valeurs de référence de gènes correspondants dérivés de sujets sans tumeur. Un processeur mettant en oeuvre le procédé interprète la signification de la surexpression et/ou de la sous-expression de ces gènes par rapport auxdites valeurs de référence pour produire une indication confirmant ou infirmant les métastases hépatiques. Les gènes spécifiques comprennent ceux du groupe 1 (PRDX4, CRP, ID1, MT1E, TNFSF14, MRC1, ICAM1, IL18, IL10, TFN) et Le groupe 2 (NGF, EPHA1, ERBB2IP, SDC1, COL18A1, KNG1, ADH1B, CYP2E1). L'analyse peut également être effectuée sur des signatures protéiques de ces gènes pour produire une indication similaire. Le procédé peut être utilisé avec un kit comprenant un réseau d'expression génétique de faible densité ou un réseau de protéines pour mesurer des expressions génétiques ou des signatures protéiques.
Latest bibliographic data on file with the International Bureau